Company profilePharmaceutical#532 of 1,318 in Pakistan✓ No DRAP alerts

VISION PHARMACUETICALS

Pharmaceutical company · 24 brands · 44 molecules

Ranked #22 of 108 companies in Macrolides, Lincosamides And Streptogramins

24 registered products 14 pharmaceutical brands 44 distinct molecules 0 DRAP alerts

Company overview

24
registered products
14
pharmaceutical brands
44
distinct molecules
6
therapeutic classes
0
DRAP alerts

VISION PHARMACUETICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 24 product registrations across 44 distinct molecules. Its portfolio is concentrated in Macrolides, Lincosamides And Streptogramins and Anaesthetic, General. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by VISION

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Chloride2 brands
Azithromycin2 brands
Ibuprofen1 brand
Ibuprofen ...... 400 Mg1 brand
Azithromycin....................250Mg1 brand
Azithromycin ...... 200 Mg1 brand
Bisoprolol ...... 5 Mg1 brand
Bisoprolol1 brand
Zoledronic Acid ...... 4 Mg1 brand

Therapeutic classes

Macrolides, Lincosamides And Streptogramins · 2Anaesthetic, General · 2Other Beta-Lactam, Cephalosporins & Penems · 2Antiinflammatory And Antirheumatic Products · 1Quinolone Antibacterials · 1Antimalarials · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official18 products · Rs 33.05 – Rs 22,510.18
Median across source: Rs 539.71

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 272 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
BIO LABS (PVT) LTD. holds 138 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
SEARLE PAKISTAN (PVT.) LTD. holds 236 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for VISION

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.